Torrent Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
October 21, 2022 at 08:28 am EDT
Share
Torrent Pharmaceuticals Limited reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was INR 22,610 million compared to INR 21,030 million a year ago. Revenue was INR 23,070 million compared to INR 21,880 million a year ago. Net income was INR 3,120 million compared to INR 3,160 million a year ago. Basic earnings per share from continuing operations was INR 9.22 compared to INR 9.32 a year ago. Diluted earnings per share from continuing operations was INR 9.22 compared to INR 9.32 a year ago.
For the six months, sales was INR 45,530 million compared to INR 42,230 million a year ago. Revenue was INR 46,840 million compared to INR 43,620 million a year ago. Net income was INR 6,660 million compared to INR 6,460 million a year ago. Basic earnings per share from continuing operations was INR 19.67 compared to INR 19.08 a year ago. Diluted earnings per share from continuing operations was INR 19.67 compared to INR 19.08 a year ago.
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.